- Home
- CSAN vs BEAM Comparison
CSAN vs BEAM Comparison
Compare CSAN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSAN
- BEAM
- Stock Information
- Founded
- CSAN 1936
- BEAM 2017
- Country
- CSAN Brazil
- BEAM United States
- Employees
- CSAN N/A
- BEAM N/A
- Industry
- CSAN Retail-Auto Dealers and Gas Stations
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSAN Consumer Discretionary
- BEAM Health Care
- Exchange
- CSAN Nasdaq
- BEAM Nasdaq
- Market Cap
- CSAN 2.3B
- BEAM 2.3B
- IPO Year
- CSAN N/A
- BEAM 2020
- Fundamental
- Price
- CSAN $5.13
- BEAM $30.43
- Analyst Decision
- CSAN Strong Buy
- BEAM Buy
- Analyst Count
- CSAN 1
- BEAM 10
- Target Price
- CSAN $19.00
- BEAM $48.75
- AVG Volume (30 Days)
- CSAN 1.2M
- BEAM 1.2M
- Earning Date
- CSAN 02-26-2025
- BEAM 03-04-2025
- Dividend Yield
- CSAN 6.75%
- BEAM N/A
- EPS Growth
- CSAN N/A
- BEAM N/A
- EPS
- CSAN 0.22
- BEAM N/A
- Revenue
- CSAN $7,655,547,290.00
- BEAM $349,643,000.00
- Revenue This Year
- CSAN $330.06
- BEAM N/A
- Revenue Next Year
- CSAN $2.09
- BEAM $14.62
- P/E Ratio
- CSAN $5.80
- BEAM N/A
- Revenue Growth
- CSAN 3.43
- BEAM 328.73
- 52 Week Low
- CSAN $4.95
- BEAM $20.84
- 52 Week High
- CSAN $14.81
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- CSAN 44.38
- BEAM 57.12
- Support Level
- CSAN $5.24
- BEAM $25.35
- Resistance Level
- CSAN $5.64
- BEAM $35.25
- Average True Range (ATR)
- CSAN 0.17
- BEAM 2.10
- MACD
- CSAN 0.02
- BEAM 0.56
- Stochastic Oscillator
- CSAN 26.28
- BEAM 55.88
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.